explore -WSS

explore

author：focus 2025-09-03 09:22:59 - browse：2473

STAT's Damian Garde speaks with Mikael Dolsten and Mathai Mammen, in New York on March 21, 2024 — From left to right, STAT's Damian Garde; Mikael Dolsten, chief scientific officer of Pfizer research and development; and Rose Loughlin, Moderna’s senior vice president of early research and development, discuss the future of pharma at the STAT 2024 Breakthrough Summit East. STAT

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday.

“We used to say, well, you may spend five years in the research phase, another five in development. Now I see a project that takes one year of research, from an idea to studies,” said Mikael Dolsten, chief scientific officer and president of Pfizer research and development. “Time is life. You care about patients. And when the distance to run is long, it holds back the energy and the inspiration.”

Key to that success are transformative new technologies like messenger RNA, which powered vaccines developed by Pfizer with its partner BioNTech.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Latest bird flu infection made farmworker sicker than earlier cases

WSS

Inari Medical to buy amputation prevention company LimFlow

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Addiction doctors spar with methadone clinics over legislation

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

How to convince healthy people to buy insurance

Scientists successfully use ultrasound imaging to map brain activity

Wikipedia

explore

hotspot

Medicare details structure of new drug price negotiation program

Inari Medical to buy amputation prevention company LimFlow

The cancer drug shortage isn’t new — and neither are the solutions

AI used to predict Covid

Tori Bowie and the unacceptable rates of Black maternal death

Addiction doctors spar with methadone clinics over legislation

Medicare proposal to cover medical devices draws a mixed reaction

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Apple is now the first public company to be valued at $3 trillion

How neuroscience research could help beat back brain cancer

focus

Startling documents reveal new facets of Sacklers' opioid empire

Inari Medical to buy amputation prevention company LimFlow

Focused ultrasound for uterine fibroids: an uphill battle

Dark money group runs ads on China biotech bill

Scientists successfully use ultrasound imaging to map brain activity

Coloradans with cystic fibrosis could lose access to Trikafta

focus

hotspot

entertainment

leisure time